Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ultra-deep sequencing of plasma DNA identifies druggable mutations in hepatocellular carcinoma

ABSTRACT: Ultra-deep sequencing of plasma DNA identifies druggable mutations in hepatocellular carcinoma

PROVIDER: PRJEB15622 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1666140.fastq.gz	Fastqsanger.gz
	ERR1666150_1.fastq.gz	Fastqsanger.gz
	ERR1666150_2.fastq.gz	Fastqsanger.gz
	ERR1666160_1.fastq.gz	Fastqsanger.gz
	ERR1666160_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 72

Similar Datasets

Ultra-deep sequencing of plasma DNA identifies druggable mutations in hepatocellular carcinoma

Project description:The purpose of the study is to detect somatic mutations in hepatocellular carcinoma using circulating free-DNA. We used deep-sequencing data of a panel of 60 commonly mutated genes in hepatocellular carcinoma.

2018-04-29 | E-MTAB-5123 | biostudies-arrayexpress

Ultra-deep shotgun sequencing

Project description:Ultra-deep shotgun sequencing

| PRJEB24152 | ENA

RNA-seq analysis of hepatocellular carcinoma plasma

Project description:RNA-seq analysis of hepatocellular carcinoma plasma

| PRJNA510411 | ENA

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.

Project description:Cellular components of solid tumors including DNA are released into the bloodstream, but data on circulating-free DNA (cfDNA) in hepatocellular carcinoma (HCC) are still scarce. This study aimed at analyzing mutations in cfDNA and their correlation with tissue mutations in patients with HCC. We included 8 HCC patients treated with surgical resection for whom we collected paired tissue and plasma/serum samples. We analyzed 45 specimens, including multiregional tumor tissue sampling (n = 24), peripheral blood mononuclear cells (PMBC, n = 8), plasma (n = 8) and serum (n = 5). Ultra-deep sequencing (5500× coverage) of all exons was performed in a targeted panel of 58 genes, including frequent HCC driver genes and druggable mutations. Mutations detected in plasma included known HCC oncogenes and tumor suppressors (e.g., TERT promoter, TP53, and NTRK3) as well as a candidate druggable mutation (JAK1). This approach increased the detection rates previously reported for mutations in plasma of HCC patients. A thorough characterization of cis mutations found in plasma confirmed their tumoral origin, which provides definitive evidence of the release of HCC-derived DNA fragments into the bloodstream. This study demonstrates that ultra-deep sequencing of cfDNA is feasible and can confidently detect somatic mutations found in tissue; these data reinforce the role of plasma DNA as a promising minimally invasive tool to interrogate HCC genetics.

| S-EPMC6035113 | biostudies-literature

RNA-seq analysis of hepatocellular carcinoma plasma

Project description:Hepatocellular carcinoma (HCC) is currently the third leading cause of death worldwide and the most common type of primary liver cancer, finding noninvasive biomarkers for HCC diagnostic and prognostic are very urging. Previous genomic studies mainly focus on finding miRNA biomarkers for HCC. In this study, we focus on finding long noncoding RNA fragments suitable for serving as hcc biomarkers with plasma and exosomal RNA-seq

2020-06-14 | GSE123972 | GEO

Differential expression profile and diagnostic value of plasma exosomal circular RNA in hepatocellular carcinoma

Project description:Circular RNAs (circRNAs) are recently found to be promising kind of biomarkers for tumors. However, plasma exosomal circRNAs in the diagnosis of hepatocellular carcinoma (HCC) is largely unknown. In this study, we report the application of next-generation sequencing technology for high-throughput profiling of plasma exosome general transcriptome between 3 cases of hepatocellular carcinoma patients and 3 cases of healthy control. We obtained exosomes through ultrahigh-speed centrifugation techniques and verified exosomes through immunoblotting, NanoSight NS300(Malvern Panalytical, Malvern, UK) and JEM-1230 transmission electron microscope (TEM) (JEOL, Tokyo, Japan). And then, we find that there are 41 circRNAs that have differential expression. This study discovered the differences between hepatocellular carcinoma and healthy people preliminarily.

2023-09-30 | GSE174179 | GEO

circRNA-sequencing analysis of plasma exosomes in hepatocellular carcinoma

Project description:circRNA-sequencing analysis of plasma exosomes in hepatocellular carcinoma

| PRJNA692609 | ENA

circRNA-sequencing analysis of plasma exosomes in hepatocellular carcinoma

Project description:Hepatocellular carcinoma (HCC) is currently the third leading cause of death worldwide and the most common type of primary liver cancer, finding noninvasive biomarkers for HCC diagnostic and prognostic are very urging. Previous genomic studies mainly focus on finding miRNA biomarkers for HCC. In this study, we focus on finding circRNA fragments suitable for serving as hcc biomarkers with plasma exosomal RNA-seq..

2021-12-01 | GSE164953 | GEO

Next Generation Sequencing Quantitative Analysis of exosomes of hepatocellular carcinoma patients and healthy people

Project description:We report the application of miRNAs analysis in exosomes based on second-generation high-throughput sequencing. Plasma samples from 3 hepatocellular carcinoma patients and 3 healthy controls were collected, and exosomes were isolated by ultra-centrifugation. MiRNAs in exosomes were then extracted and high-throughput sequencing was performed.By comparing the sequencing data, we screened out differentially expressed miRNAs and validated them with qRT-PCR in exosome samples, establishing and verifying the diagnostic panel of hepatocellular carcinoma composed of miR-212-5p, miR-519b-3p, miR-1248 and miR-1250-5p.

2024-11-14 | GSE239713 | GEO

Microarray-based ultra-high resolution discovery of genomic deletion mutations

Project description:The use of a graduated series of Arabidopsis thaliana genomic deletion mutations (of sizes ranging from 4 bp to ~5 kb) to optimize CGH-based genomic deletion detection Microarray-based ultra-high resolution discovery of genomic deletion mutations

2014-02-25 | E-GEOD-55327 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data